1
FDA Pauses PepGen’s DMD Drug Trial in the US
Monte McCullough edited this page 2 weeks ago
The therapy was being evaluated in ascending doses in the 25-week, multinational, double-blind, placebo-controlled CONNECT2-EDO51 trial. According to a PepGen news release, Titan Rise Male Enhancement the decision was tied to questions arising during the regulatory review and does not impact ongoing studies outside the US, such as the mid-stage trial in the United Kingdom and the open-label CONNECT1-EDO51 trial enrolling in Canada. PepGen expected to open the phase 2 CONNECT2-EDO51 trial in the US by end of year. PepGen did not mention a specific reason for the decision